Members of the European Parliament on Wednesday voted overwhelmingly in favor of the first pharma-related legislative overhaul in about two decades. If ultimately agreed to by the European Council, the legislative package will pave the way for slightly shorter regulatory data protection periods and new rewards to entice further investment.
The new directive and regulation, targeted at making Europe a more attractive destination for drugmakers, would make pharma companies eligible for a minimum regulatory data protection period — where other companies can’t access their product data — of seven and a half years. They’d also receive two years of market protection during which generics or biosimilars couldn’t be sold.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.